Feature

Research Reports

Implications of Manufacturer Contracting: A Quantitative Model to Assess Biosimilar Market Feasibility

10/15/2018

Abstract: Eight years have passed since Congress enacted the Biologics Price Competition and Innovation Act (BPCIA) of 2010. Since then, 12 biosimilars have received approval from the Food and Drug Administration,...

...

10/15/2018

Journal of Clinical Pathways

From the Field

Evolving the Delivery of CAR T-Cell Therapies to the Outpatient Setting

10/15/2018

James Essell , MD;

Sandy Smith , RN, MSN, AOCN;

Abstract: The availability of adoptive cell therapies allows clinicians to genetically reprogram patients’ own immune cells to find and attack cancer cells throughout the body. Chimeric antigen receptor (CAR)...

...

10/15/2018

Journal of Clinical Pathways

Perspectives

The Future of Patients as the Audience for Pathways Rather Than Providers

09/13/2018

Vivek Patkar , MBBS, MRCS, FEBS;

Guy Wood-Gush , MBBS, MBA;

Abstract: Due to technologic and societal shifts, it seems clear that patients will be much more involved in their care going forward. Health care providers and decision-makers should consider these shifting...

...

09/13/2018

Journal of Clinical Pathways

Research Reports

Community Oncologists` Perception and Acceptance of Biosimilars in Oncology

09/13/2018

Yolaine J. Jeune-Smith , PhD;

Amy Valley , PharmD;

Bruce A. Feinberg , DO;

Chadi Nabhan , MD, MBA, FACP;

Abstract: Biosimilars are hypothesized to contribute to lowering health care costs by entering the market at a discounted price compared with their reference biologics. Until recently, only filgrastim biosimilars...

...

09/13/2018

Journal of Clinical Pathways

Research Reports

KRAS/RAS Testing Is Associated With Reduced Risk of Treatment Discontinuation in Patients With Metastatic Colorectal Cancer

08/22/2018

Andrew J. Klink , PhD, MPH;

Bruce A. Bach , MD, PhD;

Urvi Mujumdar , MPH;

Bruce A. Feinberg , DO;

Alexandra Christodoulopoulou , MSc;

Marwan Fakih , MD;

Guy Hechmati , MD, MSc;

Abstract: Current clinical guidelines recommend that all patients with metastatic colorectal cancer (mCRC) have tumor tissue genotyped for RAS mutations. This study aimed to evaluate patient characteristics and...

...

08/22/2018

Journal of Clinical Pathways

Research Reports

How Oncology Care Decision-Makers Define Clinical Pathway Programs: Conceptual vs Reported Definitions

06/14/2018

Amy Schroeder , RPh;

Abstract: The American Society of Clinical Oncology (ASCO) has set forth foundational policy statements regarding the utility of clinical pathways in oncology and outlined basic requirements and aims from clinical...

...

06/14/2018

Journal of Clinical Pathways

From the Field

Establishment of Subspecialized Care in Hematologic Malignancies and a Hematopoietic Cell Transplant Program

06/08/2018

Jonathan Gerber , MD;

Zainab Shahi ;

Saad Z. Usmani , MD, FACP;

Michael R. Grunwald , MD;

Jigar Trivedi , MS, PharmD, BCOP;

Tammy Cogdill , MSN, ANP-BC, OCN;

Nilanjan Ghosh , MD, PhD;

Belinda R. Avalos , MD;

Dragos Plesca , PharmD, PhD, BCOP;

Manisha Bhutani , MD, PhD;

To read the full article, click here.

To...

06/08/2018

Journal of Clinical Pathways

Perspectives

The Evolution of Care for Acute Myeloid Leukemia and the Challenges of Defining Value

05/21/2018

William J. Cardarelli , PharmD;

Abstract: Adult acute myeloid leukemia (AML) is a cancer of the blood and bone marrow. Distinct subtypes of AML have been defined based on morphology, immunophenotyping, and molecular genetics. AML usually progresses...

...

05/21/2018

Journal of Clinical Pathways

From the Field

A Novel Clinical Pathways Approach to Delivering Regional-Based Clinical Trials and Patient Care in a Hybrid Academic-Community-Based System

05/15/2018

Kathryn E, Patronik , MHA;

Edward S. Kim , MD, FACP, MBA;

Abstract: The health care landscape is becoming constantly more complex with new drug treatments and molecular testing. In order to achieve consistent, up-to-date patient care, clinical pathways are becoming...

...

05/15/2018

Journal of Clinical Pathways

From the Field

A Community Practice Perspective on Implementation of the Oncology Care Model

05/15/2018

Anne Marie Fraley Rainey , MSN, RN, CHC;

Abstract: Clearview Cancer Institute is a private, community practice participating in the Oncology Care Model (OCM), an innovative pilot project sponsored by the Centers for Medicare and Medicaid Innovation....

...

05/15/2018

Journal of Clinical Pathways

Current Issue

October 2024

Volume 10

Issue 5

Current Issue

Issue Archive

Special Reports

Sponsored

JCP Special Report

The Value of Tissue-Based Genomic Profiling in Oncology

09/17/2024

Innovations in precision oncology have helped healthcare providers to create more personalized treatment plans and improve patient outcomes. View this special report to learn more.

Innovations in precision...

09/17/2024

Journal of Clinical Pathways

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee ;

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Robin T. Zon , MD, FACP, FASCO;

Gordon Kuntz ;

Winston Wong , PharmD;

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan ;

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Feature

Current Issue

Special Reports

Subscribe

Specialties

Events

Year Round Education

HMP Global Products